“Drugs don’t work in patients who don’t take them.” Dr. C. Everett Koop
The New York Times recently published an article on the dangers of not adhering to medications as prescribed. It was a staggering read, to say the least: the fact that, yearly, 125,000 deaths, 10% of hospitalizations, and anywhere from $100 billion to nearly $300 billion in healthcare system costs are 100% preventable by simply sticking to daily medication regimens is astonishing.
These statistics are not acceptable and there needs to be a solution. An implantable form, such as Hera Health Solutions’ biodegradable subcutaneous contraceptive Eucontra, may be the high tech answer. Hera Health Solutions is a biotech startup based in Memphis, Tennessee. They have been through the nationally ranked Zeroto510 Medical Device Accelerator Program. Their team and advisory board has decades of experience in drug development and commercialization. The development of this bioerodible product shows incredible promise in combating the issue of patient noncompliance: improving patients’ lives while reducing healthcare providers’ costs.